ReShape Lifesciences announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application 16/792,094, entitled, "Systems and Methods for Determining Failure of Intragastric Devices," related to its Obalon Balloon System. The patent will cover additional claims for the Obalon Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RSLS:
- ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
- Reshape Lifesciences Inc. (RSLS) Q4 Earnings Cheat Sheet
- ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
- ReShape Lifesciences announces formation of international SAB
- ReShape Lifesciences Announces Formation of International Scientific Advisory Board